These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23409720)

  • 21. Discovery of 2,6-Naphthyridine Analogues as Selective FGFR4 Inhibitors for Hepatocellular Carcinoma.
    Oh H; Kim J; Jung SH; Ha TH; Ahn YG; Nam G; Moon K; Singh P; Kim IS
    J Med Chem; 2024 May; 67(10):8445-8459. PubMed ID: 38706130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.
    Chen X; Liu Y; Zhang L; Chen D; Dong Z; Zhao C; Liu Z; Xia Q; Wu J; Chen Y; Zheng X; Cai Y
    Eur J Med Chem; 2021 Mar; 214():113219. PubMed ID: 33618175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells.
    Roidl A; Foo P; Wong W; Mann C; Bechtold S; Berger HJ; Streit S; Ruhe JE; Hart S; Ullrich A; Ho HK
    Oncogene; 2010 Mar; 29(10):1543-52. PubMed ID: 19946327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications.
    Ezzat S; Zheng L; Winer D; Asa SL
    Mol Endocrinol; 2006 Nov; 20(11):2965-75. PubMed ID: 16857743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FGFR4: A promising therapeutic target for breast cancer and other solid tumors.
    Levine KM; Ding K; Chen L; Oesterreich S
    Pharmacol Ther; 2020 Oct; 214():107590. PubMed ID: 32492514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fibroblast Growth Factor Receptor 4 Targeting in Cancer: New Insights into Mechanisms and Therapeutic Strategies.
    Lang L; Teng Y
    Cells; 2019 Jan; 8(1):. PubMed ID: 30634399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interrupting the FGF19-FGFR4 Axis to Therapeutically Disrupt Cancer Progression.
    Lang L; Shull AY; Teng Y
    Curr Cancer Drug Targets; 2019; 19(1):17-25. PubMed ID: 29557750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A patent review of FGFR4 selective inhibition in cancer (2007-2018).
    Quintanal-Villalonga A; Ferrer I; Molina-Pinelo S; Paz-Ares L
    Expert Opin Ther Pat; 2019 Jun; 29(6):429-438. PubMed ID: 31146605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
    Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
    Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paralog-Specific Kinase Inhibition of FGFR4: Adding to the Arsenal of Anti-FGFR Agents.
    Packer LM; Pollock PM
    Cancer Discov; 2015 Apr; 5(4):355-7. PubMed ID: 25847957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on S
    Schwarz M; Kurkunov M; Wittlinger F; Rudalska R; Wang G; Schwalm MP; Rasch A; Wagner B; Laufer SA; Knapp S; Dauch D; Gehringer M
    J Med Chem; 2024 Apr; 67(8):6549-6569. PubMed ID: 38604131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. N'-Alkylaminosulfonyl Analogues of 6-Fluorobenzylideneindolinones with Desirable Physicochemical Profiles and Potent Growth Inhibitory Activities on Hepatocellular Carcinoma.
    Chen X; Yang T; Deivasigamani A; Shanmugam MK; Hui KM; Sethi G; Go ML
    ChemMedChem; 2015 Sep; 10(9):1548-58. PubMed ID: 26214403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.
    Ho HK; Pok S; Streit S; Ruhe JE; Hart S; Lim KS; Loo HL; Aung MO; Lim SG; Ullrich A
    J Hepatol; 2009 Jan; 50(1):118-27. PubMed ID: 19008009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, Synthesis, and Biological Evaluation of 5-Formyl-pyrrolo[3,2-
    Yang F; Chen X; Song X; Ortega R; Lin X; Deng W; Guo J; Tu Z; Patterson AV; Smaill JB; Chen Y; Lu X
    J Med Chem; 2022 Nov; 65(21):14809-14831. PubMed ID: 36278929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.
    Tiong KH; Tan BS; Choo HL; Chung FF; Hii LW; Tan SH; Khor NT; Wong SF; See SJ; Tan YF; Rosli R; Cheong SK; Leong CO
    Oncotarget; 2016 Sep; 7(36):57633-57650. PubMed ID: 27192118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EGFR, HER2 target based molecular docking analysis, in vitro screening of 2, 4, 5-trisubstituted imidazole derivatives as potential anti-oxidant and cytotoxic agents.
    Guda R; Kumar G; Korra R; Balaji S; Dayakar G; Palabindela R; Myadaraveni P; Yellu NR; Kasula M
    J Photochem Photobiol B; 2017 Nov; 176():69-80. PubMed ID: 28964888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploration of N-(2-aminoethyl)piperidine-4-carboxamide as a potential scaffold for development of VEGFR-2, ERK-2 and Abl-1 multikinase inhibitor.
    Jin F; Gao D; Wu Q; Liu F; Chen Y; Tan C; Jiang Y
    Bioorg Med Chem; 2013 Sep; 21(18):5694-706. PubMed ID: 23932071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FGFR4 and its novel splice form in myogenic cells: Interplay of glycosylation and tyrosine phosphorylation.
    Kwiatkowski BA; Kirillova I; Richard RE; Israeli D; Yablonka-Reuveni Z
    J Cell Physiol; 2008 Jun; 215(3):803-17. PubMed ID: 18186042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FGFR4 Links Glucose Metabolism and Chemotherapy Resistance in Breast Cancer.
    Xu M; Chen S; Yang W; Cheng X; Ye Y; Mao J; Wu X; Huang L; Ji J
    Cell Physiol Biochem; 2018; 47(1):151-160. PubMed ID: 29763898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth.
    Ezzat S; Huang P; Dackiw A; Asa SL
    Clin Cancer Res; 2005 Feb; 11(3):1336-41. PubMed ID: 15709206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.